Berenberg Upgrades Eli Lilly Stock, Citing Room for Growth in GLP-1 Market

Investment bank Berenberg has upgraded its rating on Eli Lilly, the maker of the diabetes and weight-loss drug Mounjaro, to "buy" from "hold," according to a report by CNBC.

The upgrade reflects Berenberg's view that the pharmaceutical company has additional room to grow amid the broader boom in GLP-1 medications, a class of drugs that includes treatments for diabetes and obesity, CNBC reported, citing the firm's analysis.

GLP-1 drugs, which mimic a hormone that regulates blood sugar and appetite, have seen surging demand in recent years as pharmaceutical companies race to meet growing consumer interest in weight-loss treatments. Eli Lilly's Mounjaro, along with its related drug Zepbound, has been among the products at the center of this expansion.

Details of Berenberg's specific price target or the rationale behind the rating change beyond the GLP-1 market outlook were not immediately available in the source material.

Eli Lilly has positioned itself as a major competitor in the GLP-1 drug space alongside other pharmaceutical companies developing similar treatments, as the market for these medications continues to expand globally.